LigaChem Biosciences Balance Sheet Health
Financial Health criteria checks 5/6
LigaChem Biosciences has a total shareholder equity of ₩563.1B and total debt of ₩0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are ₩699.4B and ₩136.4B respectively.
Key information
0%
Debt to equity ratio
₩0
Debt
| Interest coverage ratio | n/a |
| Cash | ₩548.56b |
| Equity | ₩563.07b |
| Total liabilities | ₩136.37b |
| Total assets | ₩699.43b |
Recent financial health updates
Here's Why We're Not At All Concerned With LigaChem Biosciences' (KOSDAQ:141080) Cash Burn Situation
Dec 03
LigaChem Biosciences (KOSDAQ:141080) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Dec 21LigaChem Biosciences (KOSDAQ:141080) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Sep 09Here's Why LigaChem Biosciences (KOSDAQ:141080) Can Manage Its Debt Despite Losing Money
May 23Recent updates
Here's Why We're Not At All Concerned With LigaChem Biosciences' (KOSDAQ:141080) Cash Burn Situation
Dec 03After Leaping 32% LigaChem Biosciences Inc. (KOSDAQ:141080) Shares Are Not Flying Under The Radar
Nov 15An Intrinsic Calculation For LigaChem Biosciences Inc. (KOSDAQ:141080) Suggests It's 33% Undervalued
Sep 01After Leaping 26% LigaChem Biosciences Inc. (KOSDAQ:141080) Shares Are Not Flying Under The Radar
Jul 13LigaChem Biosciences Inc. (KOSDAQ:141080) Shares Could Be 33% Below Their Intrinsic Value Estimate
May 25LigaChem Biosciences' (KOSDAQ:141080) Earnings Are Weaker Than They Seem
Mar 29LigaChem Biosciences Inc.'s (KOSDAQ:141080) Share Price Could Signal Some Risk
Mar 20LigaChem Biosciences (KOSDAQ:141080) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Dec 21Risks Still Elevated At These Prices As LigaChem Biosciences Inc. (KOSDAQ:141080) Shares Dive 26%
Nov 29LigaChem Biosciences (KOSDAQ:141080) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Sep 09Here's Why LigaChem Biosciences (KOSDAQ:141080) Can Manage Its Debt Despite Losing Money
May 23A Look At The Fair Value Of LegoChem Biosciences, Inc. (KOSDAQ:141080)
Mar 29What Kind Of Shareholders Hold The Majority In LegoChem Biosciences, Inc.'s (KOSDAQ:141080) Shares?
Jan 28Estimating The Fair Value Of LegoChem Biosciences, Inc. (KOSDAQ:141080)
Dec 07
Financial Position Analysis
Short Term Liabilities: A141080's short term assets (₩595.6B) exceed its short term liabilities (₩66.4B).
Long Term Liabilities: A141080's short term assets (₩595.6B) exceed its long term liabilities (₩69.9B).
Debt to Equity History and Analysis
Debt Level: A141080 is debt free.
Reducing Debt: A141080 has no debt compared to 5 years ago when its debt to equity ratio was 3.3%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A141080 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if A141080 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/09 01:18 |
| End of Day Share Price | 2025/12/09 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
LigaChem Biosciences Inc. is covered by 7 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hyonseok Kim | CLSA |
| Haesoon Kwon | Eugene Investment & Securities Co Ltd. |
| Yeo Norae | Hyundai Motor Securities Co. Ltd. |